The latest price target for Bicara Therapeutics (NASDAQ:BCAX) was reported by HC Wainwright & Co. on January 27, 2025. The analyst firm set a price target for $45.00 expecting BCAX to rise to within 12 months (a possible 248.57% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Bicara Therapeutics (NASDAQ:BCAX) was provided by HC Wainwright & Co., and Bicara Therapeutics maintained their buy rating.

There is no last upgrade for Bicara Therapeutics

There is no last downgrade for Bicara Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicara Therapeutics was filed on January 27, 2025 so you should expect the next rating to be made available sometime around January 27, 2026.

While ratings are subjective and will change, the latest Bicara Therapeutics (BCAX) rating was a maintained with a price target of $42.00 to $45.00. The current price Bicara Therapeutics (BCAX) is trading at is $12.91, which is out of the analyst’s predicted range.